GlassScriptPhysician profile
Khalid Saifullah Ahmad
NPI 1568622397
$3,949.34
in general payments reported to CMS, 2019-2025
24 companies · $987 in 2025
The $987 reported for 2025 was more than what 87% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $277 · 2021: $495 · 2022: $549 · 2023: $577 · 2024: $589 · 2025: $987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,150 · Education: $2.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,149.75 |
| Education | $2.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,071.39 | 2019-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $985.36 | 2020-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.92 | 2019-2023 | Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $306.96 | 2019-2025 | Fasenra, Tezspire |
| Genzyme Corporation | $154.14 | 2020-2025 | |
| Kaleo, INC. | $153.97 | 2023-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $146.86 | 2025 | Neffy |
| Jazz Pharmaceuticals INC. | $143.23 | 2019-2022 | |
| Philips North America LLC | $98.89 | 2025 | Vest Therapy Und |
| Takeda Pharmaceuticals U.S.A., INC. | $75.10 | 2022-2025 | Cuvitru |
| Phadia US INC. | $70.36 | 2020-2025 | Immunocap |
| Amgen INC. | $58.78 | 2024-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $53.07 | 2019-2021 | |
| Axsome Therapeutics, INC. | $50.72 | 2024 | Sunosi |
| Azurity Pharmaceuticals, INC. | $41.98 | 2025 | Alvesco |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $34.65 | 2024-2025 | Karbinal |
| Optinose US, INC. | $33.93 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $33.09 | 2022-2023 | Ryaltris |
| Teva Pharmaceuticals USA, INC. | $24.26 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.90 | 2021 | |
| Grifols USA, LLC | $19.95 | 2023 | Xembify |
| Circassia INC. | $19.18 | 2019 | |
| X4 Pharmaceuticals, INC. | $18.26 | 2024 | Xolremdi |
| Alk-Abello, INC | $15.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.